<p>不幸的是，对于一些股东来说，<strong>InterCure Ltd.</strong>（TLV:INCR）的股价在过去三十天内下跌了 29%，延续了近期的痛苦。在过去 30 天的下跌中，股价在这一年中累计下跌了 49%。</p>
<p>由于股价大幅下跌，InterCure 目前可能看起来是一个强有力的买入机会，其市销率（&#34;P/S&#34;）为 0.7 倍，而以色列制药行业几乎一半的公司市销率超过 2.7 倍，甚至市销率高于 7 倍的情况也并不罕见。不过，仅仅将市销率视为表面数据并不明智，因为可能有解释说明其如此有限的原因。</p>
<p>我们发现 21 只美国股票预计明年将支付超过 6% 的股息收益率。查看完整列表，免费获取。</p>
<p>查看我们对 InterCure 的最新分析</p>
<p><img src="https://imageproxy.pbkrs.com/https://images.simplywall.st/asset/chart/36626000-ps-multiple-vs-industry-1-dark-2/1768364259853?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://images.simplywall.st/asset/chart/36626000-ps-multiple-vs-industry-1-dark-2/1768364259853"/></p>
<p>TASE:INCR 市销率与行业比较 2026 年 1 月 14 日</p>
<h3>InterCure 的表现如何</h3>
<p>举个例子，InterCure 的收入在过去一年中有所下降，这并不是理想的情况。市场或许认为最近的收入表现不足以跟上行业，导致市销率受到影响。然而，如果这种情况没有发生，那么现有股东可能会对股价未来的走势感到乐观。</p>
<p>想要了解公司在收益、收入和现金流方面的全面情况吗？那么我们对 InterCure 的 <strong>免费</strong> 报告将帮助您了解其历史表现。</p>
<h2>InterCure 的收入增长趋势如何？</h2>
<p>您唯一会真正感到舒适的情况是，当公司的增长明显落后于行业时，才会看到像 InterCure 这样的低市销率。</p>
<p>在回顾过去一年的财务数据时，我们感到沮丧，因为公司的收入下降了 11%。过去三年的表现也不佳，公司的收入总共缩水了 25%。因此，不幸的是，我们必须承认公司在这段时间内未能有效地增长收入。</p>
<p>与行业相比，预计在接下来的 12 个月内将实现 107% 的增长，公司的下行势头基于最近的中期收入结果，形成了一个令人警醒的局面。</p>
<p>考虑到这一点，我们理解为什么 InterCure 的市销率低于大多数同行。然而，随着收入的下滑，市销率是否已经触底并没有保证。如果公司不改善其收入增长，市销率可能会进一步下降。</p>
<h2>InterCure 市销率的底线</h2>
<p>InterCure 的市销率看起来和其股价一样疲软。一般来说，我们倾向于将市销率的使用限制在评估市场对公司整体健康状况的看法上。</p>
<p>毫无疑问，InterCure 在中期收入下滑的背景下维持其低市销率。目前，股东们接受低市销率，因为他们承认未来的收入可能也不会带来任何令人愉快的惊喜。考虑到当前的情况，如果最近的中期收入趋势持续，股价在短期内似乎不太可能出现任何显著的波动。</p>
<p>不要忘记可能还有其他风险。例如，我们已经识别出 <strong>InterCure 的 4 个警告信号</strong>（其中 1 个让我们有些不安），您应该注意。</p>
<p>重要的是要 <strong>确保您寻找的是一家优秀的公司，而不仅仅是您遇到的第一个想法。</strong> 因此，如果增长的盈利能力符合您对优秀公司的定义，请查看这份 <strong>免费</strong> 的有趣公司列表，这些公司最近的盈利增长强劲（且市盈率较低）。</p>

INCR

<p>InterCure Ltd. (TLV:INCR) 的股价在过去一个月下跌了 29%，在过去一年中下跌了 49%，引发了股东的担忧。该公司的市销率（P/S）为 0.7 倍，远低于行业平均水平的 2.7 倍，反映出收入的恶化，去年下降了 11%。随着行业预计在明年增长 107%，InterCure 的收入下降趋势暗示着前景严峻，低市销率可能尚未触底。由于公司在改善财务表现方面面临困难，股东可能面临进一步的风险</p>

<p>Unfortunately for some shareholders, the <strong>InterCure Ltd.</strong> (TLV:INCR) share price has dived 29% in the last thirty days, prolonging recent pain. The drop over the last 30 days has capped off a tough year for shareholders, with the share price down 49% in that time.</p>
<div class="lb-trans"><p>不幸的是，对于一些股东来说，<strong>InterCure Ltd.</strong>（TLV:INCR）的股价在过去三十天内下跌了 29%，延续了近期的痛苦。在过去 30 天的下跌中，股价在这一年中累计下跌了 49%。</p>
</div><p>Since its price has dipped substantially, InterCure may look like a strong buying opportunity at present with its price-to-sales (or &#34;P/S&#34;) ratio of 0.7x, considering almost half of all companies in the Pharmaceuticals industry in Israel have P/S ratios greater than 2.7x and even P/S higher than 7x aren't out of the ordinary. Although, it's not wise to just take the P/S at face value as there may be an explanation why it's so limited.</p>
<div class="lb-trans"><p>由于股价大幅下跌，InterCure 目前可能看起来是一个强有力的买入机会，其市销率（&#34;P/S&#34;）为 0.7 倍，而以色列制药行业几乎一半的公司市销率超过 2.7 倍，甚至市销率高于 7 倍的情况也并不罕见。不过，仅仅将市销率视为表面数据并不明智，因为可能有解释说明其如此有限的原因。</p>
</div><p>We've found 21 US stocks that are forecast to pay a dividend yield of over 6% next year. See the full list for free.</p>
<div class="lb-trans"><p>我们发现 21 只美国股票预计明年将支付超过 6% 的股息收益率。查看完整列表，免费获取。</p>
</div><p>See our latest analysis for InterCure</p>
<div class="lb-trans"><p>查看我们对 InterCure 的最新分析</p>
</div><p><img src="https://imageproxy.pbkrs.com/https://images.simplywall.st/asset/chart/36626000-ps-multiple-vs-industry-1-dark-2/1768364259853" alt="" original-src="https://images.simplywall.st/asset/chart/36626000-ps-multiple-vs-industry-1-dark-2/1768364259853"/></p>
<p>TASE:INCR Price to Sales Ratio vs Industry January 14th 2026</p>
<div class="lb-trans"><p>TASE:INCR 市销率与行业比较 2026 年 1 月 14 日</p>
</div><h3>How InterCure Has Been Performing</h3>
<div class="lb-trans"><h3>InterCure 的表现如何</h3>
</div><p>As an illustration, revenue has deteriorated at InterCure over the last year, which is not ideal at all. Perhaps the market believes the recent revenue performance isn't good enough to keep up the industry, causing the P/S ratio to suffer. However, if this doesn't eventuate then existing shareholders may be feeling optimistic about the future direction of the share price.</p>
<div class="lb-trans"><p>举个例子，InterCure 的收入在过去一年中有所下降，这并不是理想的情况。市场或许认为最近的收入表现不足以跟上行业，导致市销率受到影响。然而，如果这种情况没有发生，那么现有股东可能会对股价未来的走势感到乐观。</p>
</div><p>Want the full picture on earnings, revenue and cash flow for the company? Then our <strong>free</strong> report on InterCure will help you shine a light on its historical performance.</p>
<div class="lb-trans"><p>想要了解公司在收益、收入和现金流方面的全面情况吗？那么我们对 InterCure 的 <strong>免费</strong> 报告将帮助您了解其历史表现。</p>
</div><h2>How Is InterCure's Revenue Growth Trending?</h2>
<div class="lb-trans"><h2>InterCure 的收入增长趋势如何？</h2>
</div><p>The only time you'd be truly comfortable seeing a P/S as depressed as InterCure's is when the company's growth is on track to lag the industry decidedly.</p>
<div class="lb-trans"><p>您唯一会真正感到舒适的情况是，当公司的增长明显落后于行业时，才会看到像 InterCure 这样的低市销率。</p>
</div><p>In reviewing the last year of financials, we were disheartened to see the company's revenues fell to the tune of 11%. The last three years don't look nice either as the company has shrunk revenue by 25% in aggregate. So unfortunately, we have to acknowledge that the company has not done a great job of growing revenue over that time.</p>
<div class="lb-trans"><p>在回顾过去一年的财务数据时，我们感到沮丧，因为公司的收入下降了 11%。过去三年的表现也不佳，公司的收入总共缩水了 25%。因此，不幸的是，我们必须承认公司在这段时间内未能有效地增长收入。</p>
</div><p>Comparing that to the industry, which is predicted to deliver 107% growth in the next 12 months, the company's downward momentum based on recent medium-term revenue results is a sobering picture.</p>
<div class="lb-trans"><p>与行业相比，预计在接下来的 12 个月内将实现 107% 的增长，公司的下行势头基于最近的中期收入结果，形成了一个令人警醒的局面。</p>
</div><p>With this in mind, we understand why InterCure's P/S is lower than most of its industry peers. Nonetheless, there's no guarantee the P/S has reached a floor yet with revenue going in reverse. There's potential for the P/S to fall to even lower levels if the company doesn't improve its top-line growth.</p>
<div class="lb-trans"><p>考虑到这一点，我们理解为什么 InterCure 的市销率低于大多数同行。然而，随着收入的下滑，市销率是否已经触底并没有保证。如果公司不改善其收入增长，市销率可能会进一步下降。</p>
</div><h2>The Bottom Line On InterCure's P/S</h2>
<div class="lb-trans"><h2>InterCure 市销率的底线</h2>
</div><p>InterCure's P/S looks about as weak as its stock price lately. Generally, our preference is to limit the use of the price-to-sales ratio to establishing what the market thinks about the overall health of a company.</p>
<div class="lb-trans"><p>InterCure 的市销率看起来和其股价一样疲软。一般来说，我们倾向于将市销率的使用限制在评估市场对公司整体健康状况的看法上。</p>
</div><p>It's no surprise that InterCure maintains its low P/S off the back of its sliding revenue over the medium-term. Right now shareholders are accepting the low P/S as they concede future revenue probably won't provide any pleasant surprises either. Given the current circumstances, it seems unlikely that the share price will experience any significant movement in either direction in the near future if recent medium-term revenue trends persist.</p>
<div class="lb-trans"><p>毫无疑问，InterCure 在中期收入下滑的背景下维持其低市销率。目前，股东们接受低市销率，因为他们承认未来的收入可能也不会带来任何令人愉快的惊喜。考虑到当前的情况，如果最近的中期收入趋势持续，股价在短期内似乎不太可能出现任何显著的波动。</p>
</div><p>Don't forget that there may be other risks. For instance, we've identified <strong>4 warning signs for InterCure</strong> (1 makes us a bit uncomfortable) you should be aware of.</p>
<div class="lb-trans"><p>不要忘记可能还有其他风险。例如，我们已经识别出 <strong>InterCure 的 4 个警告信号</strong>（其中 1 个让我们有些不安），您应该注意。</p>
</div><p>It's important to <strong>make sure you look for a great company, not just the first idea you come across.</strong> So if growing profitability aligns with your idea of a great company, take a peek at this <strong>free</strong> list of interesting companies with strong recent earnings growth (and a low P/E).</p>
<div class="lb-trans"><p>重要的是要 <strong>确保您寻找的是一家优秀的公司，而不仅仅是您遇到的第一个想法。</strong> 因此，如果增长的盈利能力符合您对优秀公司的定义，请查看这份 <strong>免费</strong> 的有趣公司列表，这些公司最近的盈利增长强劲（且市盈率较低）。</p>
</div>

为什么投资者不应该对 InterCure Ltd.（TLV:INCR）股价暴跌 29% 感到意外